Hematology and laboratory outcomes

Results by Royston L. et al. have indicated hematological benefits in patients treated with letermovir, in particular a more robust platelet count recovery (see A).¹ By day 84 and day 180, the mean platelet count was significantly higher in the letermovir-treated patients compared to the control group (134 vs. 73 G/l or 138 vs. 92 G/l). No differences between cases and control samples were observed for neurophil and lymphocyte counts by any of the prespecified time points (see B & C).¹

At baseline, letermovir treated patient often have to deal with an impaired renal function, which is monitored by the GFR value (GFR 76 mL/min/1.73m² vs. 92 mL/min/1.73m²) (see D).¹ Over the study period, GFR was significantly better recovered in patients receiving letermovir (GFR 94 mL/min/1.73m² vs. 74 mL/min/1.73m²).¹ This effect could be related to a lower exposure to anti-CMV drugs.¹